Did you not read the letter to shareholders PR? They are filing for FDA approval this summer after trials for a human CGM. Obviously you are not familiar with diabetes, but the PR explained it very clearly. Their platform works but the industry doesn't want BGMs which is what they were using. They want CGMs.
If you can't follow the logic on the pet market then I will ignore your posts like I do your buddy. Ask a veterinarians, read some studies, look up statistics its all there and very easy to find. there are millions of pets that need a CGM 3 or 4 times a year. The Abbott Libre proves the need, but they will not support animal health. For a veterinarian to use one they have to write a prescription to the pet owner who has to go to a pharmacy and pay full price (cant use insurance) then come back for another appointment with the Vet to put it on. Not to mention there is no software for the Veterinarian to use so they have to just literally look at the pet owners phone. My vet has used one before and he said while medically it is phenomenal to get the data it is not practical so he doesnt use them. He said that a pet CGM sold to veterinarians will literally be the standard of care. if Veterinarians are going to that extreme to use the Libre (which isn't even a CGM its a flash monitor that you have to scan or lose the data every 8 hours) and they dont even make money off it because they dont sell it then its pretty obvious all the information is right about this being a big success. Not to mention ALRT is partnering with an animal health company that obviously also sees the value and further validates the market and need.
They said in the letter to shareholders they are looking to launch the human CGM with their platform the end of next year, so this gives positive cashflow until then.
If you want to hate on the company and stock and plan go right ahead, but at least try to know what you are talking about.
